Olaparib Monotherapy in Relapsed Small Cell Lung Cancer Patients With HR Pathway Gene Mutations Not Limited to BRCA 1/2 Mutations, ATM Deficiency or MRE11A Mutations

NCT03009682 · clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
15
Enrollment
OTHER
Sponsor class

Conditions

Interventions

Sponsor

Samsung Medical Center